MELVILLE, N.Y.--(BUSINESS WIRE)--Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company has received 510(k) clearance from the Food and Drug Administration (FDA) to market its laparoscopic SEER device for cutting and coagulating soft tissue. The laparoscopic SEER is a line extension of the Saline Enhance Electrosurgical Resection (SEER) device that Bovie launched earlier this year and will address the kidney resection (partial Nephrectomies) market.
The laparoscopic SEER allows the surgeon to dissect and achieve coagulation with a single device resulting in less instrument utilization and fewer instrument changes in a minimally invasive approach. The laparoscopic SEER is the second developed product in a series of new products under development based on the sintered steel technology.
In other news, the Company announced it has submitted a 510k application seeking pre-market clearance for Bovie’s line of coated blades, needles and ball electrodes. Resistick II is a coating applied to stainless steel which resists eschar (scab or scar tissue caused by burning) during surgery. The coated electrodes continue the expansion of the Bovie line of electrosurgical disposables.
For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.
This document may contain some forward looking statements, particularly regarding operational prospects in 2009 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.
